<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107013</url>
  </required_header>
  <id_info>
    <org_study_id>BTD-001 HV103</org_study_id>
    <nct_id>NCT03107013</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Mass Balance of BTD-001</brief_title>
  <acronym>HV103</acronym>
  <official_title>An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BTD-001 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balance Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Balance Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, open-label, non-randomised, single oral dose study in healthy male
      subjects to assess the mass balance recovery of carbon-14 (14C)-BTD-001.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Actual">May 1, 2017</completion_date>
  <primary_completion_date type="Actual">May 1, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass balance recovery after a single dose of carbon-14 (14C)-BTD-001</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled BTD-001 recovered in urine, faeces, and plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite Profiling</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>To provide plasma, urine and faecal samples for metabolite profiling and structural identification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of routes and rates of elimination of [14C]-BTD-001</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>[14C]-BTD-001 metabolite profiling and structural identification in plasma, urine and faeces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the chemical structure of the &quot;major&quot; metabolites of [14C]-BTD-001</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>Identification of the chemical structure of each metabolite accounting for more than 10% (by AUC) of circulating total radioactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of whole blood:plasma concentration ratios for total radioactivity</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>To evaluate the extent of distribution of total radioactivity into blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical examination</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>Safety and tolerability of BTD-001 by assessing physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety laboratory tests</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>Safety and tolerability of BTD-001 by assessingsafety laboratory tests and AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>Safety and tolerability of BTD-001 by assessing vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>Safety and tolerability of BTD-001 by assessing ECGs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>Safety and tolerability of BTD-001 by assessing physical examination AEs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cmax</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>tmax</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>time to reach maximum concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>t1/2</measure>
    <time_frame>Maximum 12 days</time_frame>
    <description>elimination half-life</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Molecular Mechanisms of Pharmacological Action</condition>
  <arm_group>
    <arm_group_label>[14C]-BTD-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-BTD-001</intervention_name>
    <description>Carbon-14 labeled BTD-001</description>
    <arm_group_label>[14C]-BTD-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged 30-65 years old

          -  BMI between18.0-35.0 kg/m2 unless investigator deems not clinically significant

          -  Regular daily bowel movements

          -  Provide written consent

          -  Agrees to protocol specified contraception

        Exclusion Criteria:

          -  Received any investigational treatment within last 3 months

          -  Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee

          -  Subjects who have previously been enrolled in this study

          -  History of any drug or alcohol abuse in the past 2 years

          -  Regular alcohol consumption in males &gt;21 units per week

          -  Current smokers and those who have smoked, including nicotine replacement or
             e-cigarates within the last 12 months.

          -  Radiation exposure, including that from the present study, excluding background
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,
             as defined in the Ionising Radiation Regulations 1999, shall participate in the study

          -  Subjects who do not have suitable veins for multiple venepunctures/cannulation as
             assessed by the investigator at screening

          -  Clinically significant abnormal lab results

          -  Positive drugs of abuse test result

          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or
             human immunodeficiency virus (HIV) results

          -  Evidence of renal impairment at screening

          -  History of or current seizure disorder or history of syncope, unexplained loss of
             consciousness or seizure in the past 3 years

          -  Clinically significant medical/psychiatric history findings, or physical/neurological
             examination findings or significant history of or current suicidal ideation or
             behaviour

          -  History of or current significant pulmonary, cardiac, renal, hepatic, chronic
             respiratory, gastrointestinal, neurological or psychiatric disease, substance
             dependence, porphyria, malignancy (with exception of local cutaneous squamous or basal
             cell carcinomas or local cervical squamous cell cancer resolved after resection) or
             hypothyroidism

          -  Subjects with QT interval corrected for heart rate according to Fridericia's formula
             &gt;450 msec

          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation
             excipients

          -  Presence or history of clinically significant allergy requiring treatment, as judged
             by the investigator. Hayfever is allowed unless it is active

          -  Donation or loss of greater than 400 mL of blood within the previous 3 months

          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other
             than up to 4 g per day paracetamol) or herbal remedies

          -  Failure to satisfy the investigator of fitness to participate for any other reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nand Signh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Ruddington</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mass Balance</keyword>
  <keyword>Phase 1</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

